For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Epidemiologic and Clinical Features of Bell’s Palsy among Children in Northern CaliforniaRowhani-Rahbar A.a · Baxter R.a · Rasgon B.b · Ray P.a · Black S.c · Klein J.O.d · Klein N.P.a
aKaiser Permanente Vaccine Study Center and bKaiser Permanente Oakland Medical Center, Oakland, Calif., cCenter for Global Health, University of Cincinnati Children’s Hospital, Cincinnati, Ohio, and dBoston University School of Medicine, Boston, Mass., USA Corresponding Author
Ali Rowhani-Rahbar, MD, MPH, PhD
Kaiser Permanente Vaccine Study Center
One Kaiser Plaza, 16th Floor
Oakland, CA 94612
Tel. +1 510 267 7502, E-Mail email@example.com
Background: Bell’s palsy (BP) is an acute, idiopathic, and usually unilateral paralysis of the facial nerve. Large population-based studies of BP among children are lacking. We determined epidemiologic and clinical features of BP among children enrolled in a large integrated health care delivery system. Methods: From 2001 through 2006, all children ≤18 years of age diagnosed with BP within the population of Kaiser Permanente Northern California were identified using the International Classification of Diseases, 9th Revision, code 351.0. All cases were adjudicated by an otolaryngologist and categorized as definite, probable, or rejected. Using chart abstraction forms, epidemiologic and clinical features of BP were determined. Results: Of a total of 977 cases initially identified, 822 (84.1%) were adjudicated as a definite or probable case. The overall incidence rate of BP during the study period was 18.8 (95% CI 17.6–20.2) per 100,000 person-years. The incidence rate increased by age and was higher in females than males across all age strata. There was no evidence for a seasonal pattern in the occurrence of BP (p for trend = 0.81). Conclusions: BP among children may be more common than previously recognized.
© 2012 S. Karger AG, Basel
Bell’s palsy (BP) is an acute, idiopathic, and usually unilateral paralysis of the seventh cranial nerve. The incidence rate of this disease ranges from 11.5 to 53.3 per 100,000 person-years in different populations [1,2,3,4,5]. BP affects all ages; some studies have suggested that the incidence rate is highest among young and middle-aged adults , while others have found a trend of increasing incidence rate with age [1,2]. BP is a diagnosis of exclusion. Known congenital (e.g., birth trauma), genetic (e.g., Melkersson-Rosenthal syndrome), and acquired (e.g., certain infections, trauma, benign and malignant tumors) causes of facial nerve paralysis need to be ruled out before the diagnosis of BP is made .
The etiology and pathophysiology of BP are not completely understood; however, infectious (e.g., reactivation of herpes simplex virus type 1 [HSV-1]), immunologic, and vascular factors have been postulated to cause BP [8,9,10,11,12]. Individuals with BP typically present with decreased forehead movement, inability to close the eye, and disappearance of the nasolabial fold on the affected side of the face [13,14]. BP is typically a self-limiting disorder with a favorable prognosis; however, its abrupt onset, rapid progression, and dramatic presentation can be frightening, especially when it occurs in a child.
Knowledge of epidemiology and clinical features of BP largely stems from studies of this disease among adults. Substantially less is known about epidemiologic and clinical features of BP among children. In this report, we provide results of a population-based study of BP among children ≤18 years of age enrolled in a large integrated health care delivery system in Northern California, USA. Our specific aims were to determine the incidence rate of BP, describe demographic characteristics of cases, and assess clinical features of the disease in this population.
This study was conducted within the population of Kaiser Permanente Northern California (KPNC) and was approved by the KPNC Institutional Review Board. KPNC is a large integrated health care delivery system with approximately 3.2 million members. The population covered by KPNC is heterogeneous with regard to age, sex, race, and socioeconomic status and represents the region’s underlying census distribution, except at extremes of income [15,16]. Therefore, investigations carried out within this population accurately approximate population-based studies. KPNC maintains a large administrative database that captures all outpatient, emergency department, and inpatient encounters within the system. Encounters authorized by KPNC providers for health plan members supplied in non-KPNC facilities as well as claims for reimbursement by health plan members that were not authorized by KPNC providers are also captured in databases.
From January 1, 2001, through December 31, 2006, all children ≤18 years of age diagnosed with BP were identified using the International Classification of Diseases, 9th Revision (ICD-9), code 351.0. Cases were included in the analysis if they were members of KPNC when diagnosed with BP. Retrospective chart reviews were conducted to extract information on demographic characteristics, history of present illness, past medical history, family history, diagnostic tests, and treatment options used for these children. Individuals identified during chart review as having had a history of BP prior to the start of the study period were excluded from the analyses. An otolaryngologist reviewed all cases using a case disposition form and categorized each as definite, probable, or rejected. The case definition for this study was developed based on a literature review and consensus among the authors (table 1).
The annual incidence rate of BP in each year from 2001 through 2006 and age- and sex-specific incidence rates of BP during the study period were calculated using the corresponding mid-year population of KPNC as the denominator. Exact 95% confidence intervals (CI) for incidence rates were calculated using the Poisson distribution. Incidence rates were separately calculated for definite cases only and definite and probable cases combined. The Cochran-Armitage test of trend was used to evaluate seasonality and secular trend in the occurrence of BP. Season was categorized into three mutually exclusive strata of ‘warm’ (May through September), ‘transitional’ (April and October), and ‘cold’ (November through March) to be consistent with the previous literature . All statistical analyses were conducted using Stata 11 (StataCorp, College Station, Tex., USA).
During the study period, 977 children ≤18 years of age were identified with an ICD-9 code for BP as indicated in their electronic records. Following chart review and adjudication, 119 children were rejected as cases. An additional 36 children were excluded from the analysis due to a previous history of BP. Of the remaining 822 children, 208 (25.3%) and 614 (74.7%) were categorized as definite and probable cases, respectively. The reasons for being classified as a probable were that involvement of all facial muscles was not noted (n = 445) and/or maximum paresis did not occur within 72 h following the onset of the initial signs (n = 355).
Demographic characteristics of the study population are shown in table 2. The majority of cases were ≥10 years of age (fig. 1). Three cases were pregnant at the time of onset of signs and symptoms. Among cases for whom data regarding family history of BP was available (n = 543), 46 (8.5%) indicated that at least one member of their family had previously been diagnosed with BP. The overall incidence rate of BP for definite cases only, and definite and probable cases combined, was 4.8 (95% CI 4.1–5.5) and 18.8 (95% CI 17.6–20.2) per 100,000 person-years, respectively. From 2001 through 2006, the annual incidence rate of BP in the study population did not change significantly (table 3; p for trend = 0.68). The incidence rate increased by age; in particular, it was noticeably higher among children ≥10 years of age. Regardless of age, the incidence rate was consistently higher among females than males (table 4). There was no evidence of a seasonal pattern in the occurrence of BP in this population (fig. 2; p for trend = 0.81).
Clinical features of cases are presented in table 5. A total of 93 (11.3%) cases were tested for blink response, 86 (92.5%) of whom tested abnormal, indicating their inability to blink due to the facial nerve palsy on the affected side of the face. Head computed tomography (CT) and magnetic resonance imaging (MRI) scans were conducted among 64 and 39 cases and reported as abnormal in 9 and 11 cases, respectively. These findings were incidental and of no etiologic significance. A total of 27 (3.3%) cases were diagnosed with recurrent BP. Of a total of 735 cases who received some treatment, 638 (86.8%), 490 (66.7%), 323 (43.9%), and 75 (10.2%) received a corticosteroid, antiviral, eye lubricant, and an antibacterial medication, respectively. A total of 453 cases (61.6%) received both prednisone and acyclovir. The overwhelming majority of patients (805/822 = 97.9%) recovered with a median time of 8 days from onset to last visit when signs and symptoms were still present.
To our knowledge, this study represents the largest population-based investigation of BP among children. Our estimated incidence rates of BP using definite cases only are consistent with those obtained in previous studies conducted in the USA [1,2,12,18]. Those studies reported incidence rates of up to 4.6 and 7.1 per 100,000 person-years among males and females 0–9 years of age, and incidence rates of up to 10.5 and 20.3 per 100,000 person-years among males and females 10–19 years of age, respectively. However, our estimated incidence rates of BP using definite and probable cases combined are higher than those reported previously in children.
This difference could stem from several factors. First, the study setting and population as well as methods of case definition and ascertainment used in those studies were different than ours. For instance, Brandenburg and Annegers [1 ]discuss that their reliance upon referral diagnosis of BP for most cases ascertained in Laredo, Tex., may have led to an underestimation of incidence rates in their study. In addition, the degree of certainty in the diagnosis of BP is not fully known or characterized in previous studies; thus, it is conceivable that a portion of true cases of BP were not included in the analysis leading to an underestimation of the incidence rate. Second, previous studies included a substantially smaller number of children with BP than our study. For instance, studies conducted in Laredo, Tex. , and Rochester, Minn. , included only 28 and 36 children with BP, respectively. Therefore, our estimates of the incidence rate of BP are more precise. Finally, it is conceivable that a portion of probable cases in our study population were not true cases of BP, which in turn resulted in an overestimation of the incidence rate when definite and probable cases were combined. However, since our definition for a definite case of BP was strict, it is likely that the incidence rate of BP among children may in fact be higher than what has been previously reported in the literature.
Consistent with the results of few studies that have reported the incidence rate of BP among children, we found an increasing trend by age [1,2,4]. Our results further suggest that the incidence rate of BP in the second decade of life is considerably higher than that in the first decade of life. The reason for such a trend is not clear. One hypothesis is the increased cumulative exposure to microbial agents by time. Specifically, several studies have indicated HSV-1 as a potential infectious etiology for BP [8,9,10]. Increased likelihood of exposure to this virus may partially explain the observed difference in the incidence rate of BP between the first and second decade of life. Other environmental and physiologic factors may also play a role; future research in this area is warranted.
Interestingly, we found a higher incidence rate of BP among females than males in our study population. A few studies with considerably smaller sample size of children have also reported a female-to-male ratio of >1 [1,2,12,19,20]. For instance, Adour et al. [12 ]found that among individuals 10–19 years of age, BP was twice as common in females and postulated that this observation may have pertained to menarche. In addition, pregnancy appears to be a risk factor for BP potentially due to physical or hormonal changes . In our study, the incidence rate of BP was higher among females than males across all age strata, even among young children, and only 3 cases were pregnant at the time of diagnosis. Future studies should assess whether the observed gender difference in this study could be potentially described by differences in the incidence rate of autoimmune disorders, infectious diseases, or other factors.
The occurrence of BP among children in this study did not show a clear seasonal pattern. Findings of previous studies with regard to the seasonality of BP are inconsistent. Some studies have suggested that the cold season is associated with a higher occurrence of BP [5,17,22,23], while others have not observed any seasonal variations [1,12,24]. None of those earlier studies evaluated the seasonality of BP in as large a study as the one used here. Future studies should assess whether an interaction exists between age, season, and geographic location in the development of BP.
Our study is subject to some limitations. First, a relatively large portion of cases were categorized as probable. As mentioned, our pre-specified definition of a definite case was strict. The documentation of the involvement of all facial muscles in a child could be quite challenging. It was not clear whether the diagnosing physician had tested a full battery of movements (e.g., moving forehead, raising eyebrows, and smiling), and even if they had, subtle changes could have been missed or not recorded. Therefore, it is conceivable that the majority of cases categorized as probable in this study were clinically definitive cases of BP. Second, race and ethnicity were unknown for some cases. Despite this limitation, we found that among cases whose ethnicity was known one half were Hispanic. Approximately 30% of children ≤18 years of age in the KPNC population are Hispanic; therefore, the distribution of ethnicity among cases in this study suggests an over-representation of Hispanics. It has been suggested that Hispanics may be more vulnerable to BP for unknown reasons ; this hypothesis requires further investigation. Third, due to the nature of the study, we did not follow up cases to fully determine the recovery status and the date of recovery. However, we did extract and present information on the date of last visit when signs and symptoms of BP were still present, and using information on the date of first visit when signs and symptoms were absent, determined the number of recovered cases. Finally, while we used a pre-specified case disposition form for adjudication of the cases, there is a need for a standard case definition of BP to facilitate comparisons across different studies. The Brighton Collaboration has formed an international working group to define BP as an adverse event following immunization . Such a case definition could be of use in future epidemiologic studies of BP.
The results of this study suggest that BP among children may be more common than previously recognized. Large studies to investigate the epidemiology and clinical features of BP among children in other settings are needed. In particular, future studies should determine the incidence rate of BP using a standard case definition and evaluate the role of gender, race, and ethnicity in the occurrence of this disease among children.
The authors wish to thank Pat Ross, Ajit DeSilva, and Joan Bartlett from the KPNC Vaccine Study Center for their contribution to this project. This study was funded by the Vaccine Safety Datalink and Clinical Immunization Safety Assessment Network through a subcontract with America’s Health Insurance Plans Vaccine Safety Fellowship Program under contract 200-2002-00732 from the United States Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position or views of the United States Centers for Disease Control and Prevention.
The authors report no conflicts of interest.
Ali Rowhani-Rahbar, MD, MPH, PhD
Kaiser Permanente Vaccine Study Center
One Kaiser Plaza, 16th Floor
Oakland, CA 94612
Tel. +1 510 267 7502, E-Mail firstname.lastname@example.org
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.